Business
Phio Pharmaceuticals Appoints Dr. John Barrett as Chief Development Officer
MARLBOROUGH, Mass., April 10, 2019 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology company developing the next generation of
About this update from Phio Pharmaceuticals Corp.
[{"type":"text","content":"MARLBOROUGH, Mass., April 10, 2019 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform, today announced the appointment of Dr. John A. Barrett as the Company's Chief Development Officer effective as of April 22nd.\nLogo - https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg \n\"I am delighted to welcome John to Phio. John is a seasoned and passionate leader who brings a wealth of experience developing immuno-oncology gene and cell therapies,\" said Dr. Gerrit Dispersyn, President and CEO of Phio Pharmaceuticals. \"His expertise in driving drug discovery and development in areas similar to Phio's current R&D focus, will be invaluable as we continue to develop our self-delivering RNAi platform into innovative immuno-oncology therapeutics. I am thrilled to have someone of John's caliber join our team, which is a testimony to the value we have developed thus far, and the potential our pipeline holds.\" \n\"Phio Pharmaceuticals' self-delivering RNAi technology is an enticing modality for immuno-oncology therapeutics with a potential to replace or complement certain genetic engineering approaches. For example, the use of this technology holds promise in taking the molecular brakes off the tumor infiltrating T-cells and releasing their full therapeutic potential,\" added Dr. Barrett. \"I am excited to join Phio and welcome the opportunity to be a part of fulfilling the Company's mission to develop truly innovative cancer treatments.\" \nDr. Barrett has accumulated over 25 years of experience working in research and development and is an expert in developing cell-based immuno-oncology therapies - such as developing intratumoral therapeutics that control gene expression levels to turn cold tumors hot, as well as CAR T-cells and TCRs. Prior to joining Phio, Dr. Barrett spent 8 years at Ziopharm Oncology, Inc., most recently serving as the Vice President of R&D and Translational Medicine. He was responsible for medical and clinical pharmacology, and all R&D activities from Discovery to Phase 2 clinical trials. Dr. Barrett holds a Ph.D. in Pharmaceutical Sciences from St. John's University and a Bachelor of Science in Biology from the State U...